Test Price
2,800 AED✅ Home Collection Available
WDR19 Gene Nephronophthisis Type 13 Genetic Test in UAE | 2800 AED | DHA Licensed
- ✓ Guarantee of Diagnostic Accuracy: 99.9% sensitivity with ISO-accredited processing.
- ✓ Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection, available daily from 8 AM to 11 PM.
- ✓ Clinical Guidance: Post‑test telephonic clinical interpretation with a DHA-licensed consultant medical geneticist.
- ✓ Insurance and Billing: Direct billing verification via WhatsApp at +971 54 548 8731.
Executive Summary and Core Metrics
The WDR19 Gene Nephronophthisis Type 13 NGS Genetic Test is a definitive DNA‑based diagnostic tool that interrogates the entire coding region of the WDR19 gene using Next‑Generation Sequencing. It identifies pathogenic variants responsible for nephronophthisis type 13, a multisystem ciliopathy affecting the kidneys, liver, and endocrine system, enabling precise clinical management and family risk assessment. This test is performed at DNA Labs UAE under DHA Facility License 1143, with a turnaround time of three to four weeks and a price of 2800 AED.
- Test Price: 2800 AED
- Turnaround Time: 3 to 4 weeks
- Sample Type: Peripheral whole blood (3-5 mL EDTA tube)
- Methodology: Next‑Generation Sequencing (NGS) – full gene sequencing
- Analytical Sensitivity: Greater than 99.9% for WDR19 exons and flanking intronic regions
- Home Collection: VIP Mobile Phlebotomy with temperature-controlled cold chain, available daily 8 AM to 11 PM
- Post‑Test Counselling: Telephonic genetic counselling with a DHA-licensed consultant medical geneticist
Test Overview and Methodology
The WDR19 gene encodes IFT144, a key component of the intraflagellar transport complex A that is essential for primary cilia function. Pathogenic variants in WDR19 disrupt ciliary signaling and lead to nephronophthisis type 13, a progressive tubulointerstitial kidney disease often accompanied by hepatic fibrosis, retinal degeneration, and endocrine abnormalities. This NGS test provides comprehensive coverage of all coding exons and conserved splice sites, delivering high-resolution detection of single‑nucleotide variants, small insertions, and small deletions.
| Feature | Our Test (WDR19 NGS) | Whole Exome Sequencing (WES) | Sanger Sequencing (Single Gene) |
|---|---|---|---|
| Precision | Greater than 99.9 percent analytical sensitivity for WDR19 exons plus flanking intronic regions | Variable; lower coverage depth for WDR19 (average 20 to 30x) | High for known variants but cannot detect novel or deep intronic mutations |
| Method | NGS (Next‑Generation Sequencing) – full gene sequencing | NGS across approximately 20,000 genes | Sanger chain‑termination method |
| Turnaround | 3 to 4 weeks | 6 to 10 weeks | 4 to 6 weeks |
| Cost Efficiency | Targeted and cost‑effective for WDR19 evaluation | Higher cost due to genome‑wide coverage | Moderate cost but limited to known variants |
Physician Insight and Safety Protocols
“An abnormal WDR19 result requires careful clinical correlation with renal, hepatic, and ocular findings. Family screening should be offered as part of a comprehensive genetic counselling plan to identify at‑risk relatives and guide early intervention strategies.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue any prescribed medication without consulting your doctor.
Exclusion Criteria and Emergency Red Flags
- Blood collection is contraindicated in patients with active infection at the venipuncture site or severe coagulopathy (INR greater than 3.0) unless medically cleared.
- Pregnancy is not an exclusion; however, pre‑test genetic counselling must address incidental findings and potential implications for the fetus.
- If you experience any of the following, seek immediate medical attention: sudden gross hematuria, oliguria (urine output less than 100 mL per 24 hours), severe flank pain with fever, or hypertensive urgency (blood pressure greater than 180/120 mmHg).
Patient FAQ and Clinical Guidance
1. What is the WDR19 gene test used for?
The WDR19 gene test identifies pathogenic mutations responsible for nephronophthisis type 13, a multisystem ciliopathy that affects the kidneys, liver, and endocrine organs. The test enables definitive diagnosis, prognostic guidance, and informed family planning for individuals with suspected hereditary kidney disease.
2. How is the test performed and what sample is required?
A simple blood draw of 3 to 5 mL in an EDTA tube is collected via a pain‑free VIP Mobile Phlebotomy service at your home. Alternatively, a drop of blood on an FTA card or pre‑extracted DNA can be submitted. The sample is transported under temperature‑controlled cold chain to our ISO‑accredited laboratory.
3. What is the turnaround time and how will I receive my results?
Results are delivered within 3 to 4 weeks in a secure digital report with a detailed clinical interpretation. Post‑test telephonic guidance is included to explain findings, discuss implications, and outline next steps with a DHA‑licensed consultant medical geneticist.
UAE Regulatory and Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License 1143 and complies with all applicable UAE federal data protection and health information laws. Patient data is processed and stored in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent follow the standards set by Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic results are handled with strict confidentiality and are accessible only to authorized healthcare professionals involved in your care.
Clinical and Logistical Metadata
| Test Name | WDR19 Gene Nephronophthisis Type 13 NGS Genetic Test |
| Price (AED) | 2800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3-5 mL EDTA tube) |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene coding region and flanking intronic regions |
| ICD-10-CM Code | Q61.8 |
| LOINC Code | 21666-2 |
| DHA Facility License and Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians